Anesthesia
Conditions
Keywords
co2 removal, anesthesia
Brief summary
The drawbacks of chemical CO2 absorbers include the production of compounds harmful to patients that also lead into increased cost and environmental impact, as well as the daily disposal of compound special waste. Sustainable management of general anesthesia is a growing concern. Continually diluting anesthetic circuits, and the disposal of chemical granulate are serious environmental problems.
Detailed description
DMF Medical has developed a next-generation CO2 filter in order to address the safety issues with current chemical CO2 absorbers in anesthesia. memsorb uses patented advanced medical membrane technology to filter CO2 from anesthetic circuits rather than absorbing via a chemical reaction. This game changing technology relies on a polymeric membrane core (similar to the ones used in oxygenators for cardiac surgery) that selectively allows CO2 to leave the rebreathing system, while maintaining the anesthetic vapor in the circuit. memsorb is a cartridge similar in size and shape to current solutions that simply clicks in place.
Interventions
DEVICEmemsorb
memsorb is a CO2 filter replacing current chemical CO2 absorbers
Sponsors
DMF Medical Incorporated
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* American Society of Anesthesiologists Physical Status Class I, II, III (low-medium risk patient) * English-speaking patients
Exclusion criteria
* Self-reported as pregnant * American Society of Anesthesiologists Physical Status Class IV (high risk patient) * Patients scheduled for emergency surgery * Documented respiratory disease, including COPD and severe asthma * Documented elevated pressure in the brain (intra cranial pressure, ICP)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| End-tidal CO2 Concentration (%) | From the start to the end of the intra-operative period for each participant | The mean concentration of carbon dioxide during the expiratory cycle, measured as a percentage (%), measured over the course of the surgical procedure. |
Countries
Canada
Contacts
PRINCIPAL_INVESTIGATOROrlando Hung, MD
Nova Scotia Health Authority
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Customized ≥ 18 years | 286 participants |
| Race and Ethnicity Not Collected | 0 Participants |
| Sex: Female, Male Female | 55 Participants |
| Sex: Female, Male Male | 144 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 111 | 0 / 175 |
| other Total, other adverse events | 0 / 111 | 0 / 175 |
| serious Total, serious adverse events | 0 / 111 | 0 / 175 |
Outcome results
None listed